anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
100 employees of a company in Rhineland Palatinate employing approximately 2100 persons will be recruited.

This is a randomized, two-armed single center study. Persons interested in study participation receive a Neuropattern™ voucher according to occupational group together with other documents. As soon as the documents (signed informed consent, evaluation form, ERI, MBI, demographic questionnaire and the form for designation of the attending physician) are returned, the study manager contacts the employee and either tells him/ her that an appointment with the designated physician should be made within the following week (Neuropattern™ group) or that there will be a three months wait (control group). The employee attends the medical appointment with the designated physician and documents sent to the physician beforehand (NPQ-A, medical clearance form and prescription form for Dexamethasone) are completed. Upon return of these documents, the Neuropattern™ test kit (including the questionnaires NPQ-P, NPQ-PSQ, NPQ-S and PHQ as well as 16 Salivettes® for saliva sample collection, 0.25 mg Dexamethasone and a portable ECG device) is shipped to the subject and Neuropattern™ is conducted at home. After return of the test kit to DAaCRO, the subject is assigned to neuropattern and will gain access to individualized online counseling for three months. Evaluation (including an evaluation form, ERI and MBI) will take place at baseline as well as three and six months after onset of online counseling for assessment of efficacy.
Patients randomized to the Experimental arm will receive a baseline educational intervention on vaccination following a vaccination history survey. Patients will be followed 6-months after the intervention to record prospective clinical data. Evidence of vaccination-status will be documented. Besides standard of care visits and testing, no additional procedures will be carried out for the purpose of this study.
there is some evidence for the role of phosphodiesterase (PDE) signaling system in pathophysiology of schizophrenia making this system a potential target for therapeutic agents. PDEs are a family of enzymes that hydrolyse cyclic nucleotides and thus play a key role in regulating intracellular levels of the second messenger cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate. Pentoxifylline (PTX) is a methylated xanthine derivative and a PDE inhibitor that is FDA-approved for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. It is known to inhibit platelet aggregation, increase erythrocyte flexibility or deformability, and reduce blood viscosity. The rationale for its use in schizophrenia is that it competitively inhibits PDEs, resulting in increased cAMP levels, the activation of protein kinase A (PKA), the inhibition of IL and TNF-α synthesis, and reduced inflammation. Furthermore, there is growing evidence to support the inflammatory hypothesis of schizophrenia, the investigators will also explore whether cytokine levels mediate the response from pentoxifylline treatment.
Devices and methods to heat and cool human beings, including inducing and maintaining hypothermia in human patients. Methods include inducing hypothermia to treat ischemic events, including heart attack and stroke, to limit damage caused by the ischemic event. Methods can include: using the lungs for heat exchange; using cooled gases for ventilation; using helium in the ventilation gas mixture, using medications to control reflex heat production; and injecting a perfluorocarbon mist into the gas stream to increase the cooling rate. The high thermal conductivity and diffusivity of helium results in greater inspired gas temperature equalization toward body temperature. Due to the latent heat of vaporization, addition of even small quantity of phase-change perfluorocarbon dramatically increases the heat carrying capacity of the respiratory gases. Hypothermia may be terminated by discontinuing the medications and warming the patient using a warmed helium-oxygen mixture.
BACKGROUND: Chinese gay, bisexual, and other men who have sex with men (GBMSM) face discrimination in many facility-based health services, thus increasing the importance of online engagement. The purpose of this study was to examine online GBMSM community spaces and implications for HIV/sexually transmitted disease prevention services.
METHODS: We conducted a total of 6 online focus group discussions with Chinese GBMSM from Guangdong province on the chat-based platform WeChat in 2021. Focus group discussions were asynchronous, and participants were able to provide and map out online spaces that they had participated in and share their perspectives on online engagement. Data were analyzed through framework analysis.
RESULTS: Overall, 48 participants participated. Most were mainly sexually attracted to men (n = 43; 90.0%) and never participated in in-person LGBTQ-related events (n = 29; 60.4%). Participants articulated a typology of online spaces along the axes of whether such spaces were Chinese platforms (vs. non-Chinese) or whether they were GBMSM-specific (vs. non-GBMSM-specific). Participants articulated several advantages of online spaces, including greater anonymity, opportunities for community building, sharing of sexual health information, and being able to meet other GBMSM more efficiently. Drawbacks included the lack of personal connection, lack of safety measures for youth, encountering deception and the use of fake profile pictures, and needing a virtual proxy network to access some websites. Participants provided suggestions to further improve their experiences of online spaces.
CONCLUSIONS: Although broad-based, GBMSM-specific messaging can be implemented in Chinese, GBMSM-specific spaces, sexual health messaging may also reach niche GBMSM communities in a variety of non-GBMSM spaces.
PURPOSE: To provide a method for selectively killing malignant neoplasms to effectively treat a nervous tumor, etc., by infecting the neoplasms with a retroviral vector containing a gene for a genetic product which can target the neoplasms for their selective death. CONSTITUTION: This method for selectively killing neoplasms comprises infecting the neoplasms with a retroviral vector containing a gene for a genetic product (e.g. thymidinekinase) capable of selectively targeting the neoplasms (e.g. malignant nervous tumor cells) for their death, further bringing the neoplasms into contact with a substance (e.g. ganciclovir) for recognizing the genetic product and selectively killing the neoplasms, and, if necessary, further applying an irradiation to the neoplasms. Thereby, the neoplasms such as malignant nervous tumor cells e.g. astrocytoma or gliocystoma, can selectively be killed. The retrovirus is preferably herpes virus which is an ecotropic wild retrovirus, etc.
PURPOSE: A Cordyceps bassiana extract having effect of treating and preventing skin inflammation including pruritus and atopic dermatitis is provided to reduce thickness of epidermal layer and reduce IgE concentration in serum. CONSTITUTION: A Cordyceps bassiana extract for preventing and treating pruritus and atopic dermatitis is an alcohol extract isolated using ethanol, propanol, or butanol. The Cordyceps bassiana alcohol extract is a butanol fraction isolated by extracting the ethanol extract with water:hexane mixture solvent and adding mixture solvent of water:butanol. A composition for preventing and treating pruritus and atopic dermatitis contains the Cordyceps bassiana alcohol extract. The composition is skin external composition. The daily dose of the composition is 0.001μg~10mg/kg.
Naproxen decreases platelet aggregation and may prolong bleeding time. In addition, because warfarin and NSAIDs are highly protein bound, the free fraction of warfarin and naproxen may increase substantially in some patients.

Concomitant use of VIMOVO and anticoagulants (such as warfarin, dicumarol and heparin) may result in increased risk of bleeding complications.

The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. 

Post-marketing reports of changes in prothrombin measures have been reported among patients on concomitant warfarin and esomeprazole therapy. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.
Participants will receive RP2D of ASP1570 along with the prophylactic steroids in a 21-day cycle. This cohort will be opened at the discretion of the sponsor.
The analysis of histopathology images with artificial intelligence aims to enable clinical decision support systems and precision medicine. The success of such applications depends on the ability to model the diverse patterns observed in pathology images. To this end, we present Virchow, the largest foundation model for computational pathology to date. In addition to the evaluation of biomarker prediction and cell identification, we demonstrate that a large foundation model enables pan-cancer detection, achieving 0.95 specimen-level area under the (receiver operating characteristic) curve across nine common and seven rare cancers. Furthermore, we show that with less training data, the pan-cancer detector built on Virchow can achieve similar performance to tissue-specific clinical-grade models in production and outperform them on some rare variants of cancer. Virchow's performance gains highlight the value of a foundation model and open possibilities for many high-impact applications with limited amounts of labeled training data.
Subjects will visit the University of Georgia (UGA) Clinical \& Translation Research Unit (CTRU) twice on consecutive days and blood will be drawn from them. On the first occasion they will be weighed and will complete the consent process. They will have been randomly assigned to the test (Stromectol) or control (placebo) group, with 8 participants in the test group and 4 participants in the control group. Stromectol will be obtained from a medical supply distributor and a placebo will be obtained through the UGA School of Pharmacy. Drugs will be prescribed by Jonathan Murrow MD. They will be stored in their original packaging at room temperature in a drug locker in the lab at CTRU. Participants will be identified by number and allocated to groups using a block randomization protocol. Randomization and drug dispensation will be done by CTRU. Eighteen ml of blood will drawn in a fasting state and they will be administered 150 mcg/kg Stromectol or the equivalent number of placebo tablets immediately after blood is drawn. Participants will remain at CTRU for four hours after they take the drug, then another 15ml of blood will be drawn. On the second day they will attend CTRU at the same time and the third blood sample will be drawn 24 hrs after administration of the drug. On each occasion the drawn blood will be coded by CTRU staff prior to being collected by a member of the Department of Infectious Diseases and taken to the laboratory (Wildlife Health G0007) for the isolation of leukocyte populations (peripheral monocytes, lymphocytes and polymorphonuclear cells (PMNs)) and for the preparation of serum. Complete blood counts will also be carried out. Sera will be analyzed on the Luminex for cytokine/chemokine content. RNA will be isolated from the cell populations for RNASeq analysis.
Checking whether changes in the perception of the quality of life related to health, after the nursing intervention, influence these patients' motivation to change. This was a two-staged study undertaken in entertainment-sector workers in Spain: the first part was transversal and observational, and the second was semi-experimental. First part undertook in 284 entertainmentsector workers, selected by non-probabilistic sampling, while second part undertook in 50 entertainment-business workers, selected by consecutive sampling from those who consumed substances. A short group-based motivational intervention session was implemented by nursing staff, and a before and after evaluation was completed. The EuroQol-5D and Test for the Evaluation of the Quality of Life in Addicts to Psychoactive Substances (TECVASP) were used. The patients' motivation to change was evaluated through the Stages of Change Readiness and Treatment Eagerness Scale.
PROBLEM TO BE SOLVED: To obtain a remedy of anesthetic injury especially useful for curing of injury by an inhalation anesthetic, containing a bonding inhibitor of P-selectin as an active component. SOLUTION: This remedy contains a bonding inhibitor of P-selectin as an active component. As the bonding inhibitor, the one inhibiting bonding to a ligand on a leukocyte by bonding to P-selectin, and a manifestation inhibitor of P-selectin are preferable. As the former, e.g. an anti-P-selectin antibody PB 1.3 is exemplified. As the latter manifestation inhibitor, e.g. a nitrogen monoxide donor such as S-nitroso-thiols is exemplified. Preferably, the objective remedy is administrated into vein and in the intravenous administration, the remedy may be used by dissolving or suspending in an aqueous carrier such as water, physiological saline, etc. The remedy is preferably administrated in an effective component amount of 5-3,000mg/day for a patient having 70kg body weight. The remedy can also be used as a preventive.
PURPOSE: To obtain the hair-raising agent containing the solvent extract of chestnut bur, exhibiting an excellent hair-raising action, and guaranteed in safety. CONSTITUTION: The hair-raising agent contains as an active ingredient an extract which is obtained by extracting chestnut bur with water or a hydrophilic organic solvent (e.g. ethanol) and, if necessary, lyophilizing the extraction solution into the powder. The active ingredient is suitably compounded with other cosmetic raw materials such as a liquid oil (e.g. squalane), a solid oil (e.g. beeswax), a humectant (e.g. glycerol), various active agents and various medicinal agents, and subsequently prepared into a lotion, a cream, an emulsion, a pack, etc. Since the bur of the chestnut having been supplied as a food over many years is used as a raw material, the safety of the hair-raising agent for human bodies is guaranteed, and the hair-raising agent stimulates the generation and growth of hair.
Circumscribed choroidal haemangioma (CCH) is an uncommon, potentially congenital benign vascular hamartomas which typically manifests as an elevated mass with reddish-orange pigmentation located posteriorly to the equator, mostly in the macular and peripapillary region. Despite its benign nature, cystoid macular edema (CME) or SRF due to the exudations from the exudative CCH can cause visual impairment. Diagnosis is often suspected clinically, and multimodal imaging is useful for the differential diagnosis of CCH from other malignant tumors such as melanoma. Optical coherence tomography angiography (OCTA) is a rapid, non-invasive, new imaging technology which could provide the capillary density (CD) of superficial and deep capillary plexus as well as the CD of choriocapillaris of the superficial, the latter two of which could not be seen on conventional FA or ICGA. However, little knowledge is known about the parafoveal microvasculature changes in eyes with exudative CCH on OCTA. Therefore, it is necessary to quantitative evaluation of parafoveal microvasculature changes in eyes with exudative CCH compared with healthy eyes without any disease. To the best of our knowledge, this is the first cross-sectional, case-control study to use OCTA to quantitative evaluation of parafoveal microvasculature changes in Eyes with exudative CCH compared with age- and gender-controlled healthy eyes.
Softgels having improved stability of active pharmaceutical ingredients and methods of preparing the same are provided. In some embodiments, a softgel comprises a fill material composition and a softgel shell. In some embodiments, the fill material composition of the softgel comprises one or more active pharmaceutical ingredient (API); 2 to 15 wt. % povidone; 30 to 60 wt. % polyethylene glycol; and 0.5 to 5 wt. % propylene glycol, wherein the fill material composition has a pH of 3.75 or less. In some embodiments, the softgel shell is made from a softgel shell composition comprising an acidic component.
Emtricitabine: Following oral administration, emtricitabine is rapidly absorbed with peak plasma concentrations occurring at 1–2 hours post-dose. Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the steady-state plasma emtricitabine Cmax was 1.8 ± 0.7 µg/mL (mean ± SD) and the AUC over a 24-hour dosing interval was 10.0 ± 3.1 µg∙hr/mL. The mean steady state plasma trough concentration at 24 hours post-dose was 0.09 µg/mL. The mean absolute bioavailability of emtricitabine was 93%. In vitro binding of emtricitabine to human plasma proteins is <4% and is independent of concentration over the range of 0.02–200 µg/mL. Following administration of radiolabelled emtricitabine, approximately 86% is recovered in the urine and 13% is recovered as metabolites. The metabolites of emtricitabine include 3'-sulfoxide diastereomers and their glucuronic acid conjugate. Emtricitabine is eliminated by a combination of glomerular filtration and active tubular secretion with a renal clearance in adults with normal renal function of 213 ± 89 mL/min (mean ± SD). Following a single oral dose, the plasma emtricitabine half-life is approximately 10 hours.
It will be planned as 3 sets of 10 repetitions resistance exercises with 50% of 1 maximum repetition. Exercises will be performed on chest press, pectoral, pulley, hip abductor and adductor, leg press, cable biceps curl, triceps push down, shoulder press, abdominal crunch machines. The program will be created with a rest period of 3 minutes between sets, 10 minutes of stretching before the exercise and 10 minutes of stretching and cooling exercises after the exercise.
Schistosomiasis is a major public health issue. Clinical guidelines for the management of imported schistosomiasis are heterogeneous. The objective of this study is to describe the clinical management of schistosomiasis imported cases in France, regarding diagnosis, treatment and follow-up. It is a multicentric, retrospective, descriptive study. Inclusion criteria are an age ≥ 18, a positive western blot and / or a positive microscopy exam. Data concerning clinical presentation, biological samples, imaging, treatment and follow-up will be assessed. A descriptive analysis will be performed.
Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
NEW MATERIAL:EC 40 of the formula having 121-124 deg.C melting point and C15H21NO20 molecular formula. USE:Having a lipoperoxide production inhibition effect and useful as a preventive and a remedy for disease symptoms such as various diseases, inflammations or edemas due to hindrance of circulation in brain, heart, periphery, etc. Useful also as an antioxidant for foods. PREPARATION:The compound of the formula is obtained by culture of an microorganism. As the strain, an EC 40-producing strain belonging to Streptomyces genus, specifically Streptomyces chrestomyceticus EC 40 strain (FERM BP-3032) is used and an aerobic liquid culture is preferably carried out in a suitable culture medium. Culture temperature is suitably 20-37 deg.C, especially preferably 25-30 deg.C. EC 40 is collected from the cultured material, e.g. by extraction using ethyl acetate, etc.
A method for determining a missing value of a physiological feature of interest for a target patient is disclosed. The method comprises accessing, for a plurality of recorded patients, patient information including recorded values for a plurality of features including the physiological feature of interest and one or more additional features. Target patient information for the target patient is obtained, comprising values for the one or more additional features. For each recorded patient, the method comprises determining a measure of similarity between said patient and the target patient based on the one or more additional features. A subset of patients which are similar to the target patient are selected, based on the measures of similarity. If the difference between a population measure for the subset and for the plurality of recorded patients is statistically significant, the method comprises assigning a value to the feature of interest for the target patient based on the values of the physiological feature of interest of the subset of patients.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of maintaining powdery state in a dry manner for a long time without adhesion of crystal precipitating by sublimation of a menthol on the inner wall of a bathing agent container by pulverizing a menthol solution using a pulverizing agent after dissolving the menthol in a perfume, etc., to prepare the composition. SOLUTION: This composition is prepared by dissolving (A) a menthol of the formula (e.g. 1-menthol, etc.), in (B) a perfume (e.g. a floral-type mixed fragrance, etc.), and/or a solvent (preferably, propylene glycol or 1,3-butylene glycol) and pulverizing a menthol solution using (C) a pulverizing agent (preferably, fine powdered silicic anhydride or calcium silicate). A preferable formulation ratio of each component, is in an amount of about 0.5-2.0 wt.% component A based on the total weight of the composition, the sum of component B is about 20-75 wt.% based on the component A and the amount of the component C is about 50-100 wt.% based on the sum of the components A and B.
OBJECTIVE: To analyze the effect of breastfeeding on reducing Pentavalent vaccination pain in infants and to identify the necessary breastfeeding interval for antinociceptive action.
METHOD: Open parallel randomized clinical trial. Ninety mother-infant dyads participated, distributed into intervention group 1 (n = 30), which breastfed five minutes before vaccination; intervention group 2 (n = 30), which breastfed five minutes before and during vaccination; and control group (n = 30), which did not breastfeed. The outcome variable was the pain level measured by the FLACC Scale. Data analysis was conducted using descriptive and inferential statistics, applying Fisher's Exact, Kolmogorov-Smirnov, Kruskal-Wallis and Dunn's multiple comparison tests, with 0.05 significance level.
RESULTS: Pain induced by the Pentavalent vaccine was reduced in intervention groups 1 and 2 (mean pain of 6.06 versus 3.83, respectively) compared to the control group (mean of pain of 7.43), which was significant for intervention group 2 (p < 0.001), indicating that, to achieve lower levels of pain, breastfeeding should be carried out before and during vaccination.
CONCLUSION: Longer breastfeeding, conducted five minutes before and during vaccination, reduces the pain induced by the Pentavalent vaccine. No vaccination risks were identified to outweigh the benefits. These results endorse that health professionals should encourage breastfeeding at least five minutes before and during vaccine injection for an antinociception effect. Brazilian Clinical Trials Registry: RBR-9vh37wr.